Today: 27 February 2026
Subscribe
Browse Category

NYSE:ABBV 21 December 2025 - 8 January 2026

AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie shares fell 3.7% to $224.84 Thursday after the company denied takeover talks with Revolution Medicines and flagged a $1.3 billion fourth-quarter charge tied to R&D and milestone payments. AbbVie trimmed its 2025 profit forecast, setting adjusted earnings at $9.90 to $9.94 per share. Revolution Medicines dropped 5.5%. Wolfe Research downgraded AbbVie, citing limited upside.
8 January 2026
··
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie shares fell 1.6% to $229.64 premarket after the company denied talks to acquire Revolution Medicines and cut its 2025 profit forecast. Revolution stock dropped 11.5% following AbbVie’s statement. AbbVie now expects 2025 adjusted EPS of $9.90 to $9.94, down from its previous outlook, citing a $1.3 billion acquired IPR&D charge. Earnings are due Feb. 4.
8 January 2026
···
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie shares fell 1% to $231.11 in after-hours trading after the company denied reports of takeover talks with Revolution Medicines. A new SEC filing flagged a $1.3 billion fourth-quarter charge, prompting AbbVie to cut its 2025 adjusted earnings forecast to $9.90–$9.94 per share from $10.61–$10.65. Revolution shares dropped 11.5% late.
8 January 2026
····
AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

AbbVie stock flat premarket after Canada OKs Maviret for acute hepatitis C — what investors watch next

Health Canada approved AbbVie’s Maviret for acute and chronic hepatitis C in adults and children aged 3 and older. AbbVie shares were flat premarket at $220.18 after falling nearly 4% Monday. The approval followed a Priority Review based on Phase 3 data. Investors await AbbVie’s Jan. 14 appearance at the J.P. Morgan Healthcare Conference.
6 January 2026
··
AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie stock slides 4% as pharma lags Wall Street rally — what investors watch next for ABBV

AbbVie shares closed down 4% at $220.18 on Monday, underperforming a market rally that sent the Dow to a record. Trading volume reached 8.9 million shares, well above the 50-day average. The stock now sits below key technical levels ahead of its Jan. 14 presentation at the J.P. Morgan Healthcare Conference and expected late-January earnings.
6 January 2026
·····
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie shares rose 0.2% to $228.95 after Ironwood Pharmaceuticals, its Linzess partner, raised 2026 U.S. net sales guidance and cut the drug’s list price effective Jan. 1. Ironwood shares jumped 29.5%. Ironwood now expects 2026 Linzess U.S. net sales of $1.125–$1.175 billion, up from 2025’s $860–$890 million forecast. Wall Street trading was muted as investors awaited U.S. labor data and watched for broader drug pricing moves.
2 January 2026
···
AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie Stock (ABBV) Holds Near $230 as Year-End “Santa Rally” Takes Shape; Dividend Boost, Legal Headlines and 2026 Outlook in Focus

AbbVie closed Friday at $229.98, near its 52-week high, as U.S. markets ended a quiet post-holiday session with major indexes little changed. No major AbbVie corporate news broke in the past two days, but investor analysis and institutional filings kept the stock in focus. Institutions and hedge funds hold about 70% of shares. The next regular trading session is Monday.
27 December 2025
···
AbbVie Stock (ABBV) Before the Market Opens Dec. 26, 2025: Today’s News, Earnings Outlook, Dividend Update, and Analyst Forecasts

AbbVie Stock (ABBV) Before the Market Opens Dec. 26, 2025: Today’s News, Earnings Outlook, Dividend Update, and Analyst Forecasts

AbbVie shares closed at $229.89 in a shortened Dec. 24 session, near their 52-week high of $244.81. The company reported Q3 2025 net revenues of $15.776 billion, with Skyrizi and Rinvoq sales outpacing declining Humira revenue. Markets reopen Dec. 26 after the Christmas holiday. AbbVie recently announced a dividend increase effective February 2026.
26 December 2025
·
AbbVie (ABBV) Stock After Hours Today (Dec. 23, 2025): Key News, Forecasts, and What to Watch Before the Market Opens Dec. 24

AbbVie (ABBV) Stock After Hours Today (Dec. 23, 2025): Key News, Forecasts, and What to Watch Before the Market Opens Dec. 24

AbbVie shares closed at $228.79 Tuesday, up 0.4%, and traded near $229.60 after hours. Trading volume was thin ahead of Wednesday’s early market close for Christmas Eve. Investors tracked U.S. drug pricing talks, AbbVie’s pipeline beyond Botox, and a late legal update on Orilissa. AbbVie remains in its 52-week range of $164 to $245.
24 December 2025
··
AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie shares traded near $228.62 Tuesday afternoon, up 0.31%, as investors weighed new pipeline updates and continued debate over U.S. drug pricing. PharmaVoice reported AbbVie is advancing two next-generation neurotoxins, AGN-151607 and TrenibotE, for both aesthetic and therapeutic uses. Nasdaq highlighted strong Skyrizi and Rinvoq sales, projecting over $25 billion combined in 2025.
23 December 2025
·
AbbVie Stock After Hours (ABBV): Shares Dip After the Bell on Dec. 22, 2025 — Key News, Forecasts, and What to Watch Before Tuesday’s Open

AbbVie Stock After Hours (ABBV): Shares Dip After the Bell on Dec. 22, 2025 — Key News, Forecasts, and What to Watch Before Tuesday’s Open

AbbVie shares closed up 0.48% at $227.91 Monday, then slipped to about $226.05 in early after-hours trading. The move followed news that AbbVie remains a holdout on federal drug-pricing deals, with White House meetings expected after the holidays. Trading volume reached about 4.8 million shares. The stock sits below its early-October peak of $244.81.
23 December 2025
··
AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie Stock News Today (Dec. 22, 2025): ABBV Holds Near $227 as Drug-Pricing Talks, Dividend Growth, and 2026 Catalysts Come Into Focus

AbbVie shares traded at $227.73 midday Monday, near recent highs, as the company remains one of three major drugmakers not signed onto the White House’s new “most-favored-nation” drug-pricing agreements announced December 19. Investors are watching for AbbVie’s next move on the policy front, while its core immunology drugs and dividend growth continue to anchor fundamentals.
22 December 2025
···
AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie closed at $226.82 on Friday, Dec. 19, up 1.8%, with trading volume spiking to 18.6 million shares, well above average. The company remains in talks with the White House as U.S. drug pricing reforms accelerate, including “most-favored-nation” deals and new TrumpRx programs. AbbVie is expected to visit the White House after the holidays for further negotiations.
22 December 2025
···
AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie shares closed at $226.82 on Friday, December 19, up 1.8% on heavy volume ahead of a holiday-shortened week. The company was not included in the White House’s December 19 list of drugmakers agreeing to new MFN pricing deals, leaving policy risk unresolved. Investors are watching for further announcements that could affect sentiment and trading.
21 December 2025
··
1 2 3 4 5
Go toTop